[
  {
    "ts": "2025-12-09T00:30:02+00:00",
    "headline": "These 2 High-Yield Dividend Stocks Are Some of the Safest Buys Right Now",
    "summary": "Merck and Duke Energy stand out as rare “safe yield” plays, pairing 3%+ dividends with solid earnings growth, reasonable payout ratios, and durable demand drivers in healthcare and regulated utilities.",
    "url": "https://www.barchart.com/story/news/36517612/these-2-high-yield-dividend-stocks-are-some-of-the-safest-buys-right-now",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "704dd210-cb84-37d5-95f4-a99fb131fc6b",
      "content": {
        "id": "704dd210-cb84-37d5-95f4-a99fb131fc6b",
        "contentType": "STORY",
        "title": "These 2 High-Yield Dividend Stocks Are Some of the Safest Buys Right Now",
        "description": "",
        "summary": "Merck and Duke Energy stand out as rare “safe yield” plays, pairing 3%+ dividends with solid earnings growth, reasonable payout ratios, and durable demand drivers in healthcare and regulated utilities.",
        "pubDate": "2025-12-09T00:30:02Z",
        "displayTime": "2025-12-09T00:30:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/7a001c013d6478f36b63c9346edbba82",
          "originalWidth": 1600,
          "originalHeight": 1054,
          "caption": "Money bag with the word Dividends by Andrii Yalanskyi via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8AbXQLuHyuWf6J2NZjhbww--~B/aD0xMDU0O3c9MTYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/barchart_com_477/7a001c013d6478f36b63c9346edbba82.cf.webp",
              "width": 1600,
              "height": 1054,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Ljd0Jvh1WDKM3R0BdHhrVg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/7a001c013d6478f36b63c9346edbba82.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/36517612/these-2-high-yield-dividend-stocks-are-some-of-the-safest-buys-right-now",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-high-yield-dividend-stocks-003002095.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DX-Y.NYB"
            },
            {
              "symbol": "GC=F"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "DUK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T10:27:00+00:00",
    "headline": "Strategic Pharma Collaborations Propel RCC Market Growth",
    "summary": "The global advanced renal cell carcinoma (RCC) market is experiencing rapid growth driven by innovative treatment approaches, rising disease awareness, and an expanding patient base. Key factors include the adoption of targeted therapies and immunotherapies, personalized medicine, and strategic collaborations among industry leaders such as Pfizer, Merck & Co., and AstraZeneca.Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The \"Advanced Renal Cell Carcinoma (RCC) Market - A Global and Regional Analysi",
    "url": "https://finance.yahoo.com/news/strategic-pharma-collaborations-propel-rcc-102700645.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "a91df546-a5ff-36e2-878b-8d7e920eac4f",
      "content": {
        "id": "a91df546-a5ff-36e2-878b-8d7e920eac4f",
        "contentType": "STORY",
        "title": "Strategic Pharma Collaborations Propel RCC Market Growth",
        "description": "",
        "summary": "The global advanced renal cell carcinoma (RCC) market is experiencing rapid growth driven by innovative treatment approaches, rising disease awareness, and an expanding patient base. Key factors include the adoption of targeted therapies and immunotherapies, personalized medicine, and strategic collaborations among industry leaders such as Pfizer, Merck & Co., and AstraZeneca.Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The \"Advanced Renal Cell Carcinoma (RCC) Market - A Global and Regional Analysi",
        "pubDate": "2025-12-09T10:27:00Z",
        "displayTime": "2025-12-09T10:27:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/strategic-pharma-collaborations-propel-rcc-102700645.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/strategic-pharma-collaborations-propel-rcc-102700645.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "AZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T12:45:00+00:00",
    "headline": "Ability Biotherapeutics Appoints Angèle Maki, PhD, as Chief Business Officer",
    "summary": "MONTREAL, December 09, 2025--Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business Officer (CBO).",
    "url": "https://finance.yahoo.com/news/ability-biotherapeutics-appoints-ang-le-124500304.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "8654457b-10f6-3ef1-b66c-16c9de109f1f",
      "content": {
        "id": "8654457b-10f6-3ef1-b66c-16c9de109f1f",
        "contentType": "STORY",
        "title": "Ability Biotherapeutics Appoints Angèle Maki, PhD, as Chief Business Officer",
        "description": "",
        "summary": "MONTREAL, December 09, 2025--Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business Officer (CBO).",
        "pubDate": "2025-12-09T12:45:00Z",
        "displayTime": "2025-12-09T12:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/3ae5467b75c2baa421cf3f0ab3c28d5b",
          "originalWidth": 480,
          "originalHeight": 252,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/i5nsAYtH3_5LzijGf1BhIg--~B/aD0yNTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/3ae5467b75c2baa421cf3f0ab3c28d5b.cf.webp",
              "width": 480,
              "height": 252,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VNoj2CLtePDlXa5DlK442w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/3ae5467b75c2baa421cf3f0ab3c28d5b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ability-biotherapeutics-appoints-ang-le-124500304.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ability-biotherapeutics-appoints-ang-le-124500304.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T12:40:36+00:00",
    "headline": "How Protein And Pets Drove Elanco Animal Health's 79% Gain In 2025",
    "summary": "Elanco Animal Health CEO Jeff Simmons says the company is in the best position it's been in years. Elanco stock has surged in 2025.",
    "url": "https://www.investors.com/news/technology/elanco-stock-elanco-animal-health-investor-day/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "9bab0fc5-6295-3099-b7bb-d8809da91fdb",
      "content": {
        "id": "9bab0fc5-6295-3099-b7bb-d8809da91fdb",
        "contentType": "STORY",
        "title": "How Protein And Pets Drove Elanco Animal Health's 79% Gain In 2025",
        "description": "",
        "summary": "Elanco Animal Health CEO Jeff Simmons says the company is in the best position it's been in years. Elanco stock has surged in 2025.",
        "pubDate": "2025-12-09T12:40:36Z",
        "displayTime": "2025-12-09T12:40:36Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/9bab0fc5-6295-3099-b7bb-d8809da91fdb/how-protein-and-pets-drove.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/7c192be627ef42493f4b8a8e27b370ab",
          "originalWidth": 1012,
          "originalHeight": 572,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5_nr4lIyP5CRz.zpQNyiMw--~B/aD01NzI7dz0xMDEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/7c192be627ef42493f4b8a8e27b370ab.cf.webp",
              "width": 1012,
              "height": 572,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aKFfExh3jhw9NBZtT4erJQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/7c192be627ef42493f4b8a8e27b370ab.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/elanco-stock-elanco-animal-health-investor-day/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ELAN"
            },
            {
              "symbol": "ZTS"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]